Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DG1CX7
|
|||
| Drug Name |
ABO-101
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Mucopolysaccharidosis [ICD-11: 5C56.3; ICD-9: 277.5] | Phase 1/2 | [1] | |
| Company |
Abeona Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-N-acetylglucosaminidase (NAGLU) | Target Info | . | [1] |
| KEGG Pathway | Glycosaminoglycan degradation | |||
| Metabolic pathways | ||||
| Lysosome | ||||
| Reactome | HS-GAG degradation | |||
| WikiPathways | Glycosaminoglycan metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Abeona Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.